PNU-177864
PNU-177864 is a potent, selective, orally active dopamine D3 receptor antagonist. PNU-177864 induces phospholipid metabolism in vivo and has anti-schizophrenia activity[1][2][3].
Product Specifications
CAS Number
250266-51-4
UNSPSC
12352005
Target
CCR; Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Metabolic Disease; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/pnu-177864.html
Purity
99.49
Solubility
DMSO : 57.14 mg/mL (adjust pH to 5 with HCl)
Smiles
O=S(C1=CC=C(OC(F)(F)F)C=C1)(NC2=CC=C(CCNCCC)C=C2)=O
Molecular Formula
C18H21F3N2O3S
Molecular Weight
402.43
References & Citations
[1]Rudmann DG, et al. Epididymal and systemic phospholipidosis in rats and dogs treated with the dopamine D3 selective antagonist PNU-177864. Toxicol Pathol. 2004 May-Jun;32 (3) :326-32.|[2]Vonderfecht SL, et al. Myopathy related to administration of a cationic amphiphilic drug and the use of multidose drug distribution analysis to predict its occurrence. Toxicol Pathol. 2004 May-Jun;32 (3) :318-25.|[3]Liana Basova , et al. Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS One.2018 Jun 26;13 (6) :e0199861.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CCR5
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
